Mast cell activation test: A new asset in the investigation of the chlorhexidine cross-sensitization profile.
CD63
chlorhexidine
cross-reactivity
flow cytometry
human mast cells
mast cell activation
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
24
01
2022
received:
07
12
2021
accepted:
01
03
2022
pubmed:
20
3
2022
medline:
27
10
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
Insights into the IgE cross-sensitization and possible cross-reactivity patterns of sera reactive to chlorhexidine (CHX) are still incomplete and are likely to benefit from a functional exploration using a passive mast cell activation test (pMAT). Therefore, we want to study whether the pMAT with CHX-specific IgE (sIgE) enables to depict effector cell degranulation in response to alexidine (ALX), octenidine (OCT) and/or polyhexamethylene biguanide (PHMB) indicative of cross-reactivity between these compounds and CHX. Serum of 10 CHX-allergic patients, nine individuals with an isolated sIgE CHX and five healthy controls were included. Human cultured mast cells (MCs) were, before and after sensitization, challenged with CHX, ALX, OCT or PHMB. Degranulation was measured via quantification of upregulation of CD63. Mast cell responsiveness to ALX and OCT was demonstrable with 4/10 and 3/10 of the sera of CHX-allergic patients respectively. Percentage of degranulation varied between 12 and 34% for ALX-reactive MCs and between 4 and 22% for OCT-reactive MCs. No reactivity to ALX or OCT was demonstrable when using sera obtained from individuals with an isolated sIgE CHX or from healthy controls. Unlike CHX, ALX and OCT, PHMB turned out to be a direct MC activator via occupation of MRGPRX2. PHMB-reactive sIgEs were demonstrable in some patients with an isolated sIgE CHX but were unable to trigger PHMB-induced degranulation in MRGPRX2 knockdown MCs. Mast cells constitute an attractive tool to explore cross-reactivity between structurally similar compounds. Along with the identification of safe alternatives for the individual patient, the pMAT can advance our insights into sIgE cross-reactivity patterns including assessment of molecules not yet approved for human use.
Sections du résumé
BACKGROUND
Insights into the IgE cross-sensitization and possible cross-reactivity patterns of sera reactive to chlorhexidine (CHX) are still incomplete and are likely to benefit from a functional exploration using a passive mast cell activation test (pMAT). Therefore, we want to study whether the pMAT with CHX-specific IgE (sIgE) enables to depict effector cell degranulation in response to alexidine (ALX), octenidine (OCT) and/or polyhexamethylene biguanide (PHMB) indicative of cross-reactivity between these compounds and CHX.
METHODS
Serum of 10 CHX-allergic patients, nine individuals with an isolated sIgE CHX and five healthy controls were included. Human cultured mast cells (MCs) were, before and after sensitization, challenged with CHX, ALX, OCT or PHMB. Degranulation was measured via quantification of upregulation of CD63.
RESULTS
Mast cell responsiveness to ALX and OCT was demonstrable with 4/10 and 3/10 of the sera of CHX-allergic patients respectively. Percentage of degranulation varied between 12 and 34% for ALX-reactive MCs and between 4 and 22% for OCT-reactive MCs. No reactivity to ALX or OCT was demonstrable when using sera obtained from individuals with an isolated sIgE CHX or from healthy controls. Unlike CHX, ALX and OCT, PHMB turned out to be a direct MC activator via occupation of MRGPRX2. PHMB-reactive sIgEs were demonstrable in some patients with an isolated sIgE CHX but were unable to trigger PHMB-induced degranulation in MRGPRX2 knockdown MCs.
CONCLUSION
Mast cells constitute an attractive tool to explore cross-reactivity between structurally similar compounds. Along with the identification of safe alternatives for the individual patient, the pMAT can advance our insights into sIgE cross-reactivity patterns including assessment of molecules not yet approved for human use.
Substances chimiques
Chlorhexidine
R4KO0DY52L
polihexanide
322U039GMF
Biguanides
0
alexidine
GVN71CAL3G
Immunoglobulin E
37341-29-0
Receptors, G-Protein-Coupled
0
MRGPRX2 protein, human
0
Nerve Tissue Proteins
0
Receptors, Neuropeptide
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1320Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Ohtoshi T, Yamauchi N, Tadokoro K, et al. IgE antibody-mediated shock reaction caused by topical application of chlorhexidine. Clin Allergy. 1986;16:155-161.
Opstrup MS, Jemec GBE, Garvey LH. Chlorhexidine allergy: on the rise and often overlooked. Curr Allergy Asthma Rep. 2019;19:23.
Pham NH, Weiner JM, Reisner GS, Baldo BA. Anaphylaxis to chlorhexidine. Case report. Implication of immunoglobulin E antibodies and identification of an allergenic determinant. Clin Exp Allergy. 2000;30:1001-1007.
Mueller-Wirth N, Buenter A, Jörg L, et al. IgE-mediated chlorhexidine allergy-Cross-reactivity with other biguanide disinfectants. Allergy. 2020;75:3237-3247.
Elst J, van der Poorten MM, Faber MA, et al. Mast cell activation test in chlorhexidine allergy: a proof of concept. Br J Anaesth. 2020;125:970-975.
Elst J, Moonen N, van der Poorten MM, et al. The passively sensitized mast cell activation test is a reliable diagnostic for chlorhexidine allergy. J Allergy Clin Immunol Pract. 2021;9(10):3826-3828.e2.
Garvey LH, Ebo DG, Mertes PM, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy. 2019;74:1872-1884.
Cop N, Decuyper II, Faber MA, et al. Phenotypic and functional characterization of in vitro cultured human mast cells. Cytometry B Clin Cytom. 2017;92:348-354.
Dreborg S. Methodological cutoff of basophil activation test and basophil activation test diagnostic value. J Allergy Clin Immunol Pract. 2018;6:1089-1090.
Matsson P, Hamilton R, Esch R, et al. Analytical Performance Characteristics and Clinical Utility of Immunological Assays for Human Immunoglobulin E (IgE) Antibodies and Defined Allergen Specificities: Approved Guideline. Clinical and Laboratory Standards Institute; 2009.
Elst J, Sabato V, Faber MA, et al. MRGPRX2 and immediate drug hypersensitivity: insights from cultured human mast cells. J Investig Allergol Clin Immunol. 2021;31(6):489-499.
Elst J, Maurer M, Sabato V, et al. Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluoroquinolones. Front Immunol. 2021;12: 668962.
Baldo BA, Pham NH. Drug Allergy: Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships. Springer-Verlag; 2013.
Ebo DG, Van der Poorten ML, Elst J, et al. Immunoglobulin E cross-linking or MRGPRX2 activation: clinical insights from rocuronium hypersensitivity. Br J Anaesth. 2021;126:e27-e29.
Varricchi G, Pecoraro A, Loffredo S, et al. Heterogeneity of human mast cells with respect to MRGPRX2 receptor expression and function. Front Cell Neurosci. 2019;13:299.
Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy. 2006;61:935-939.
Ebo DG, Bridts CH, Mertens CH, Sabato V. Principles, potential, and limitations of ex vivo basophil activation by flow cytometry in allergology: a narrative review. J Allergy Clin Immunol. 2021;147:1143-1153.
Ebo DG, Elst J, Van Gasse A, et al. Basophil activation experiments in immediate drug hypersensitivity: more than a diagnostic aid. Methods Mol Biol. 2020;2163:197-211.
Ludwig D. Measurement of mast cell and basophil activation in vitro as means for investigation of drug hypersensitivity. Medicine. England: Southampton, 2015. https://eprints.soton.ac.uk/416617/